FDA Revises EUA for Use of Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis Prevention for COVID-19
FDA revised the emergency use authorization for bamlanivimab and etesevimab (administered together) to include emergency use as post-exposure prophylaxis (prevention) for COVID-19.
On Sept. 16, 2021, FDA revised the emergency use authorization (EUA) for bamlanivimab and etesevimab (administered together) to include emergency use as post-exposure prophylaxis (prevention) for COVID-19 in patients 12 years of age and older who weigh at least 40 kg and are at high risk for progression to severe COVID-19, including hospitalization or death. Bamlanivimab and etesevimab are monoclonal antibodies (mAbs).
Bamlanivimab and etesevimab (administered together) are now authorized for use after exposure to the SARS-CoV-2 virus in this revision of the EUA. The mAbs are not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the virus.
These mAbs may only be used when administered together as post-exposure prophylaxis for patients 12 years of age and older weighing at least 40 kg who:
- Are at high risk for progression to severe COVID-19, including hospitalization or death
- Are not fully vaccinated or who are not expected to have an adequate immune response to complete COVID-19 vaccination
- Have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria, per the CDC
- Are at high risk of exposure to an individual infected with SARS-CoV-2 in the same institutional setting (such as nursing homes)
In addition, bamlanivimab and etesevimab (administered together) remain authorized for the treatment of mild to moderate COVID-19 in patients 12 years of age and older weighing at least 40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
